Breaking News, Financial News

4Q Financial Reports: Biogen Idec

Biogen Idec

4Q Revenues: $633 million (+8%)

4Q Earnings: $56 million (+94%)

FY Revenues: $2.4 billion (+10%)

FY Earnings: $161 million (+541%)

Comments: Revenues for the quarter and full year were driven by Rituxan and Avonex. Rituxan revenues were up 15% to $709 million and Avonex sales were up 9% to $1.5 billion for the year. Rituxan revenues were up 6% to $182 million and Avonex sales were up 12% to $413 million for the quarter. Revenues for the quarter and full year included $182 million and $709 million, respectively, from Biogen Idec’s joint business arrangement with Genentech, related to Rituxan.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters